Targeted cancer therapy allows the delivery of therapeutic agents to cancer cells without incurring undesirable side effects on the neighboring healthy tissues. Over the past decade, there has been an increasing interest in the development of advanced cancer therapeutics using targeted nanoparticles. Here we describe the preparation of drug-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2-fluoropyrimidine ribonucleic acid aptamers that recognize the extracellular domain of prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells. We show that the self-assembled nanoparticles can selectively bind to PSMA-targeted prostate cancer cells in vitro and in vivo. This formulation method may contribute to the development of highly selective and effective cancer therapeutic and diagnostic devices.
Introduction
Nanomaterials have unique physicochemical properties, such as large surface area-to-mass ratios and high surface reactivity, which are different from bulk materials of the same composition. These unique physical properties allow the materials to interact with the human body on the molecular scale with a high degree of specificity. The application of nanotechnology in medicine, also known as nanomedicine, involves the use of precisely engineered nanomaterials for medical diagnosis and therapeutic treatments (1) . One of the most exciting research topics in nanomedicine is targeted drug delivery. By combining molecular targeting capabilities and controlled drug release properties, targeted drug delivery offers the possibility of achieving precision-guided drug delivery to individual diseased cells with minimal side effects on neighboring healthy cells (2, 3) .
as a model controlled release polymer system; and polyethylene glycol (PEG) as a model hydrophilic polymer with antibiofouling properties, to develop a proof-of-concept NP-Apt that is potentially suitable for selectively targeting PSMA PCa cells in vitro and in vivo. 9. The resulting PLGA-b-PEG block copolymer was precipitated with ether/methanol washing solvent and washed with the same solvent to remove unreacted PEG.
10.
The resulting purified PLGA-b-PEG block copolymer was dried under vacuum and used for NP preparation without further treatment (see Note 4) .
11.
The composition of PLGA-b-PEG was characterized using a 400 MHz 1 H nuclear magnetic resonance (Bruker, Bill-erica, MA, USA). The nuclear magnetic resonance (NMR) characterization sample was prepared by dissolving 5 mg of the PLGA-b-PEG diblock copolymer in 1 mL of deuterated chloroform (CDCl 3 ). An example of a PLGA-b-PEG NMR spectrum is shown in Fig. 1 .
Nanoparticle Preparation Methods

Nanoprecipitation for Encapsulating of Hydrophobic Compounds
1. PLGA-b-PEG (10 mg/mL) and docetaxel (0.1 mg/mL) were dissolved in acetonitrile.
2.
The PLGA-b-PEG and docetaxel mixture was added drop wise to three to five volumes of stirring water (see Note 5), giving a final polymer concentration of 3.3 mg/mL.
3.
The NPs were stirred for 2 h, and the remaining organic solvent was removed in a rotary evaporator at reduced pressure.
4.
The NPs were concentrated using Amicon ultracentrifugation at 4,000 × g for 15 min and washed with deionized water and reconstituted in PBS.
5.
The particle size and size distribution can be measured by dynamic light scattering (Brookhaven Instruments Corporation 90 plus particle sizer, 676-nm laser) at 25°C and at a scattering angle of 90° at a concentration of approximately 1 mg NP/mL water (see Note 6).
Double Emulsion (w/o/w) for Encapsulating Hydrophilic Compounds
1. An aqueous solution of rhodamine-labeled dextran (2.5 mg/mL, 0.4 mL) was emulsified in 2 mL PLGA-b-PEG dissolved in DCM (50 mg/mL) using a probe sonicator (Fisher Scientific, Pittsburgh, PA, USA) at 20 W for 45 s.
7.
The cell culture chamber slides were then mounted and visualized by fluorescent microscopy (see Note 7).
8.
Where indicated, the number of nanoparticle aptamer biocon-jugates or control nanoparticles attached to individual LNCaP or PC3 cells was quantified by fluorescent microscopy under oil immersion at 100× magnification (see Note 8) . A sample figure of targeted NP uptake by LNCaP and PC cells is shown in Fig. 3 .
Initial volume of the tumors averaged 328 mm 3 . Tumor efficacy study results are shown in Fig. 4 . 
